Welcome to Diurnal

A global specialty pharmaceutical company focused on chronic endocrine diseases

Diurnal Group plc is a European, UK-headquartered specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.

Mission Statement

To address the major unmet clinical and patient needs in endocrinology by creating products for the lifelong treatment of chronic conditions.

bio image

Overview

Diurnal is committed to transparency in its interactions. Diurnal commits to following the Association of British Pharmaceutical Industry (ABPI) Code of Practice which has clear requirements for transparency. Diurnal has published details of its transfers of value required under the ABPI Code on the ABPI website and on this website. Diurnal has gone beyond the requirements of the ABPI code by publishing all of its transfers of value worldwide.

Clinical Trial Data Access Request

Diurnal is committed to public disclosure and transparency of our clinical study data. Diurnal is committed to transparency in clinical trials and publishes the protocols and results of its clinical trials on the website Diurnal agrees to share upon request from qualified scientific and medical researchers patient- and study-level clinical study data and protocols from clinical studies in patients for medicines and indications approved by national regulatory authorities.

Diurnal Group plc (Company Number: 09846650) is registered in England & Wales. Registered office: Cardiff Medicentre, Heath Park, Cardiff CF14 4UJ, UK.